Stockwatch: Competing for attention
This article was originally published in Scrip
This has been a week of dull news and JPMorgan is to blame. The Scrip electronic post-bag has been overflowing with press releases on Interim Management Statements, reviews of recent achievements, and minor service deals dressed up as strategically significant developments. In short, a lot of companies have been fairly desperate to find something new to say to the media to decorate their appearance at the year’s first and – some would argue – most important investment conference of the year.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.